Conjugate of wt1-derived peptides and composition comprising the same

Abstract

The present disclosure includes a compound of formula (1): wherein cancer antigen peptide A is an MHC class I-restricted peptide consisting of 7 to 30 amino acid residues and containing at least one cysteine residue, wherein the cysteine residue of the cancer antigen peptide A binds to R1 via a disulfide bond; and R1 is hydrogen, a group of formula (2), the group of formula (3), or cancer antigen peptide D, wherein the group of formula 2 is wherein Xa and Yd independently represent a single bond or a divalent peptide group consisting of 1 to 4 amino acid residues, provided that the sum of the number of amino acid residues in Xa and Ya is an integer of 0 to 4, and the cancer antigen peptide B is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues, wherein the amino group of the N-terminal amino acid of the cancer antigen peptide B binds to Ya in the formula (2), and the carbonyl group of the C-terminal amino acid of the cancer antigen peptide B binds to the hydroxyl group in the formula (2), and the formula (1) and the formula (2) binds via a disulfide bond, the group of formula (3) is wherein Xb and Yb independently represent a single bond or a divalent peptide group consisting of 1 to 4 amino acid residues, provided that the sum of the number of amino acid residues in Xb and Yb is an integer of 0 to 4, and the cancer antigen peptide C is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues, wherein the carbonyl group of the C-terminal amino acid of the cancer antigen peptide C binds to Xb in the formula (3), and the amino group of the N-terminal amino acid of the cancer antigen peptide C binds to the hydrogen atom in the formula (3), and the formula (1) and the formula (3) binds via a disulfide bond, and the cancer antigen peptide D is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues and containing at least one cysteine, wherein the cysteine residue of the cancer antigen peptide D binds to R1 via a disulfide bond; or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.